Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility Implantation Failure
Conditions
Infertility Implantation Failure
Trial Timeline
Apr 1, 2003 → Apr 1, 2004
NCT ID
NCT00504608About Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) is a phase 1/2 stage product being developed by Merck for Infertility Implantation Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00504608. Target conditions include Infertility Implantation Failure.
What happened to similar drugs?
16 of 20 similar drugs in Infertility Implantation Failure were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00504608 | Phase 1/2 | Completed |
| NCT00504530 | Phase 1/2 | Completed |
Competing Products
20 competing products in Infertility Implantation Failure